Premium
Scleral crosslinking as a therapeutic approach to treat progressive myopia
Author(s) -
ISELI HP
Publication year - 2014
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2014.2715.x
Subject(s) - blue light , retinal , elongation , retina , ophthalmology , riboflavin , medicine , chemistry , materials science , biology , biochemistry , ultimate tensile strength , optoelectronics , neuroscience , metallurgy
Elongation of the bulbus is the main cause of high myopia. Light induced scleral crosslinking is suggested as a therapeutic approach to prevent extensive eye elongation . Data about efficient light intensities and light‐induced damage threshold of retinal tissue are not conclusive. There are no data available about the effect on eye growth of light induced crosslinking in an animal model. Material an methods In vitro and in vivo experiments in rabbits were performed with riboflavin/blue light application for scleral crosslinking. Mechanical stiffening effects were studied by means of rheology and tissue damage threshold were characterized by histology and electron microscopy. Results Collagen Crosslinking by riboflavin/blue light stiffens the scleral tissue and induced a significant reduction of eye growth in young rabbits without damaging effects on retinal tissue. Conclusion Riboflavin/Blue light treatment might be a promissing treatment to control eye growth and therefore, to prevent high myopia. More investigations are needed to establish optimal treatment parameters.Commercial interest